Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tribbles homolog 1 (TRIB1) is a highly conserved pseudokinase that acts as an adapter/scaffolding protein rather than a phosphotransferase, due to its non-functional ATP-binding domain and atypical SLE motif[1][2][3][4][6]. TRIB1 regulates cellular processes by binding MAPK pathway components and modulating the activity and degradation of critical transcription factors, notably C/EBPα. It is widely expressed and plays major roles in hematopoietic cell differentiation, macrophage polarization, immune response, lipid metabolism, and carcinogenesis[1][2][3][6]. TRIB1's ability to modulate signaling and protein stability makes it a significant therapeutic target and potential biomarker in oncology, metabolic syndrome, cardiovascular disease, and immune regulation, although no specific drugs directly targeting TRIB1 are approved thus far.
Potential inhibitors would likely disrupt TRIB1's scaffold/adaptor function and its interaction with substrates (such as C/EBPα) or effectors (such as MAPK, MEK1/2, Akt, JAK/STAT, COP1). Modulation of TRIB1-mediated protein degradation (e.g., through the ubiquitin-proteasome system). Alteration of downstream MAPK, PI3K/Akt, ERK, JNK signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tribbles homolog 1 (TRIB1).